

News Release



Media Contact:

Garrett D. Smith

Phone: 240.238.4914

gsmith@accelovance.com

Accelovance Prepares for Continued Growth; Adds to Senior Management Team

Rockville, MD – February 16, 2010 – Accelovance, a CRO with a proven approach to reduce timelines and optimize productivity, announced today two additions to its senior management team; Joseph W. Angle, Jr. has been appointed Chief Financial Officer and Lisa Beth Ferstenberg, MD has been appointed Chief Medical Officer (CMO). These additions come after another 12 month period of continued growth for Accelovance and recent recognition as “Best CRO” vaccine industry excellence award winner.

“We are pleased with our continued growth in 2009; more than 35% versus the prior year top line results,” commented President & CEO Stephen J. Trevisan. “Mr. Angle and I have worked together in the past to build successful companies. His leadership will strengthen our organization. Dr. Ferstenberg brings to the company great depth and experience in regulatory, biopharmaceutical and medical device development with over 25 years in the industry.”

Mr. Angle will lead the financial and administrative functions at Accelovance after serving as interim CFO for the last six months. He has recently been a consulting CFO to several Washington, DC area companies, Mr. Angle has over 15 years of experience in the drug development industry. He previously co-founded several companies with Accelovance CEO, Stephen J. Trevisan, including TherImmune Research Corporation, CommSys Corporation and National Clinical Research Centers (NCRC). Mr. Angle helped manage each company to profitability and year-after-year double digit revenue growth.

As CMO, Dr. Ferstenberg’s clinical research experience and executive background enhances the capabilities of the CRO and Regulatory divisions of the company. Prior to joining Accelovance, Dr. Ferstenberg founded and served as CEO for Collective Therapeutics, Inc., an immunology focused biotech company which was later sold to MedImmune Corporation. Her balanced perspective of science, technology, regulatory and business provide valuable clinical development direction for Accelovance clients. Furthermore, she has in-depth experience in international regulatory affairs, manufacturing operations, quality assurance, business development, FDA submissions and IPO preparation. Therapeutic areas of expertise include vaccines, infectious diseases, oncology, immunology, drug delivery systems, devices and diagnostics, neurology and psychiatric disorders.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. The company was recognized as “2009’s Best CRO” with an Industry Excellence award. Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor’s needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company’s website at <http://www.accelovance.com>.